← Back to headlines
IDEAYA Stock Slips After Delaying Uveal Melanoma Trial Results
IDEAYA Biosciences experienced a stock decline following its announcement of a delay in releasing results from its darovasertib uveal melanoma trial.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
